ATRA Atara Biotherapeutics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ATRA Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$5.22
Analyst Target
$8.67
+66.0%
Upside
52W High
$19.14
52W Low
$4.2
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.
Key Strengths
Recent quarterly earnings have consistently beaten estimates, with an average surprise of +242% over the last four quarters
Gross margin remains relatively strong at 46.76%, suggesting some pricing power or cost control in core operations
Current price of $5.22 is significantly below the growth-based intrinsic value estimate of $20.02, implying potential upside if fundamentals stabilize
ROA of 30.86% is positive and unusually high for a biotech firm, though likely distorted by asset write-downs or accounting adjustments
Low Price/Sales ratio of 0.25 suggests the market is pricing in extreme pessimism, potentially creating contrarian opportunity
Key Risks
Piotroski F-Score of 2/9 indicates very weak financial health, with red flags across profitability, leverage, and operating efficiency
Operating margin of -102.72% reflects unsustainable cost structure and lack of path to profitability
Revenue has collapsed by 91.4% year-over-year, signaling severe commercial or operational challenges
Insiders have sold $0.61M in shares over the past 6 months with zero buys, indicating strong lack of confidence from management
Technical trend score of 0/100 and 1-year price decline of 24.7% (with 5-year loss of 98.9%) reflect deep market skepticism and momentum breakdown
AI Fair Value Estimate
Based on comprehensive analysis
$12.5
+139.5% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ATRA against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ATRA from our newsroom.
Newest → oldest
No matching news yet.